Deerfield Management Company, L.P. (Series C) Janux Therapeutics, Inc. Put Options Transaction History
Deerfield Management Company, L.P. (Series C)
- $4.35 Billion
- Q2 2025
Put Options
0 transactions
| Quarter | Operation | Price Per put | puts change | puts Held | SEC Form |
|---|
Others Institutions Holding JANX
# of Institutions
188Shares Held
56MCall Options Held
869KPut Options Held
652K-
Ra Capital Management, L.P. Boston, MA11.2MShares$319 Million5.65% of portfolio
-
Janus Henderson Group PLC London, X04.46MShares$127 Million0.05% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY2.92MShares$83.3 Million3.15% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA2.53MShares$72 Million0.1% of portfolio
-
Black Rock Inc. New York, NY2.34MShares$66.8 Million0.0% of portfolio
About Janux Therapeutics, Inc.
- Ticker JANX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 41,663,000
- Market Cap $1.19B
- Description
- Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth ...